Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.
CAS Registry Number
14838-15-4
Molecular formula
C9H13NO
Molecular weight
151.21 g/mol
Drug class
Sympathomimetic aminepredominantly indirect adrenergic agonist and nasal decongestant
Mechanism of action
Primarily promotes norepinephrine release from sympathetic nerve terminals and also has direct agonist activity at adrenergic receptors. Alpha-adrenergic activity causes vasoconstriction of nasal mucosal vessels; beta-adrenergic effects may also occur.
Indications / reported uses
Historically used as an oral or topical nasal decongestant in some jurisdictions; current availability and permitted indications vary because of safety-related regulatory restrictions.
It has also been used as an appetite suppressant historically; this is not presented as a current routine therapeutic indication.
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
ERA assessment scope
Project-specific environmental risk assessment support
The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.
Phase I exposure screening and trigger evaluation.
Environmental fate and ecotoxicity review, with Phase II work where required.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope
Environmental Risk Assessment (ERA)
ReguSight provides project-specific support for the Phenylpropanolamine Environmental Risk Assessment (ERA) (the Phenylpropanolamine ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.
Assessment may cover
Product, active-substance identity, formulation, route and intended-market review.
Phase I environmental exposure screening and applicable trigger evaluation.
Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
Data-gap analysis, study strategy, assumptions and scientific reporting.
The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.